CD34 and acute myeloid leukemia: The HAP evofosfamide (TH-302) has demonstrated drug-dependent cytotoxicity against primary AML cells and the leukemia stem-cell enriched compartment (CD34+ CD123+ cells) under hypoxic conditions with minimal cytotoxicity against normal BM samples.